onvapegleukin alfa (TransCon IL-2 β/γ) / Ascendis 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
onvapegleukin alfa (TransCon IL-2 β/γ) / Ascendis
2022-001191-34: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Not yet recruiting
2
287
Europe
TransCon IL-2 β/γ, KEYTRUDA, TransCon TLR7/8 Agonist, ACP-016, ACP-017, Concentrate for solution for infusion, Suspension for injection
Ascendis Pharma Oncology Division A/S, Ascendis Pharma Oncology Division A/S
locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, Locally Advanced or Metastatic Solid Tumor Malignancies, Diseases [C] - Cancer [C04]
 
 
BelieveIT-201, NCT05980598: TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
2
92
Europe, US, RoW
TransCon TLR7/8 Agonist, Pembrolizumab, Keytruda™, TransCon IL-2 β/γ
Ascendis Pharma A/S
Head and Neck Neoplasms
04/25
07/27
IL Believe, NCT05081609: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Recruiting
1/2
393
Europe, Canada, US, RoW
TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery
Ascendis Pharma Oncology Division A/S
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer
05/26
08/27

Download Options